Evercore ISI analyst Gavin Clark-Gartner resumed coverage of BioCryst (BCRX) with an Outperform rating and $17 price target The strategic move with the Astria Therapeutics (ATXS) acquisition positions BioCryst well for long-term growth, says the analyst, who notes Orladeyo is expected to reach a $900M sales peak by 2029 and sees navenibart potentially hitting $1B in risk-adjusted sales.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BioCryst reports inducement grants under Nasdaq listing rule
- BioCryst Closes Blackstone Loan and Astria Acquisition
- BioCryst completes acquisition of Astria Therapeutics
- Astria stockholders vote to approve acquisition by BioCryst
- BioCryst: Sustained Orladeyo Momentum, Disciplined Financials, and Pipeline Upside Support Buy Rating